AKT1 and melanoma: To investigate whether the inhibition of the PI3K/Akt pathway improved the sensitivity of melanoma cells to the BRAFi, cells were treated with LY294002, a PI3K inhibitor, in combination with dabrafenib and assessed for the cell viability.